Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Kidney stone formation due to an excess of calcium in the urine is a common problem. It is treated with thiazide diuretics. These drugs often cause excessively low blood potassium levels that in turn require large doses of potassium supplements. These supplements are often large, unpleasant and easy to forget. We are trying the addition of spironolactone to these patients' medications to see if it allows them to take a lower dose of potassium.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University School of Medicine
• Treatments: Diuretics; Sodium Chloride Symporter Inhibitors; Spironolactone

Criteria

Inclusion Criteria:

• Age 18-65

• History of idiopathic hypercalciuria (>200mg per 24 hours or a Ca/cr ratio of >140) felt to be the primary etiology of patient's kidney stones

• History of at least three kidney stone events

• On same dose of thiazide diuretic for at least three months

• On stable dose of K 60mEq or more a day to maintain serum K >3.5 or unable to tolerate an increase in K supplement with dose at least 40mEq a day

Exclusion Criteria:

• Use of ACE inhibitor, ACE receptor blocker or other medication known to effect serum potassium levels

• GFR <80 by MDRD equation

• Serious cardiac disease, diabetes, CKD , current or planned pregnancy or breastfeeding

• History of hypertension